A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects
NCT05913752
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this study is to find the tolerable dose and characterize the safety and pharmacokinetics/ pharmacodynamics (PK/PD) of single and repeated dose of CMND-100 in Healthy Volunteers (HV) and Subjects with Alcohol Use Disorder (AUD). The secondary objective of this study is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in subjects with moderate to severe AUD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Alcohol Use Disorder
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Clearmind Medicine Inc.
- Last updated on ClinicalTrials.gov
- March 31, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Connecticut Mental Health Center · New Haven, CT
Maryland · 1
- Johns Hopkins Bayview Medical Center · Baltimore, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.